Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Blood (2025) 146 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2025-3391

Published: 2025

Journal Articles

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

Blood (2025) 146 (Supplement 1): 5182.

https://doi.org/10.1182/blood-2025-5182

Published: 2025

Journal Articles

The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory chronic graft-versus-host disease

Yibo Wu, Lizhen Liu, Yi Chen, Xiaoyu Lai, Ying Lu, Luxin Yang, Lin Li, Lan Sun, Junjie Cao, Jimin Shi, Xiaolin Yuan, Panpan Zhu, He Huang, Yi Luo

Blood (2025) 146 (Supplement 1): 7761.

https://doi.org/10.1182/blood-2025-7761

Published: 2025

Journal Articles

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Hang Yang, Peng SUN, Panpan LIU, Yu Wang, Hui Zhou, Ying Lu, Lu Zhang, Keshu Zhou, Zhiming Li

Blood (2025) 146 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2025-1922

Published: 2025

Journal Articles

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Linjie Li, Beili Hu, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2025-1911

Published: 2025

Journal Articles

AP-3 targets the mrgbp/Tip60/MYC axis to exert potent anti T-ALL effects in a Notch1 independent manner

Fenglin Li, Haihui Zhuang, Jie Jin, Ying Lu

Blood (2025) 146 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2025-3364

Published: 2025

Journal Articles

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: A multi-center study in China

Ya-nan Ma, Wenzhi CAI, Hongming Zhu, Ying Lu, Xiaofei Yang, Jian-xin Guo, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 7347.

https://doi.org/10.1182/blood-2025-7347

Published: 2025

Journal Articles

Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent control

Xiaoqian Xu, Ying Lu, Weiying Bao, Xiuhua Han, Ran An, Ying Wang, Zhiyin Liu, Jie Tian, Xingying Li, Zeying Yan, Haimin Sun, Li Chen, Sujiang Zhang

Blood (2025) 146 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2025-3447

Published: 2025

Journal Articles

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2025-1907

Published: 2025

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Peipei Ye, Renzhi Pei, Lihong Shou, Jie Jin, Hongyan Tong, Huifang Jiang, Linlong Xu, Jian Shen, Sai Chen, Gongqiang Wu, Dong Chen, Shuangyue Li, Jingcheng Zhang, Huang Li, Fujiang Song, Weiying Feng, Chao Hu, Ying Lu

Blood (2025) 146 (Supplement 1): 5960.

https://doi.org/10.1182/blood-2025-5960

Published: 2025

Journal Articles

Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia

Nianci Chen, Yu Zhu, Zhenqi Huang, Ying Lu, Yinjun Lou, Liping Mao, Xinping Zhou, Dan Chen, Lihong Shou, Huang Li, Cuihua Fan, Hongyan Tong, Jie Jin, Huafeng Wang, East China Leukemia Alliance (Ecla)

Blood (2025) 146 (Supplement 1): 5237.

https://doi.org/10.1182/blood-2025-5237

Published: 2025

Journal Articles

Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial

Peipei Ye, Renzhi Pei, Jie Jin, Hongyan Tong, Lihong Shou, Huifang Jiang, Jingcheng Zhang, Sai Chen, Linlong Xu, Yanping Shao, Dong Chen, Shuangyue Li, Huang Li, Jing le, Yangxi Jin, Chao Hu, Ying Lu

Blood (2025) 146 (Supplement 1): 4182.

https://doi.org/10.1182/blood-2025-4182

Published: 2025

Journal Articles

A prospective, multicenter study on stem cell mobilization using EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma

Blood (2025) 146 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2025-4179

Published: 2025

Journal Articles

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Blood (2025) 145 (18): 2012–2024.

https://doi.org/10.1182/blood.2024026446

Published: 2025

Includes: Supplemental data

Journal Articles

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Yafang Ma, Xiang Zhang, Jian Hou, Lijing Shen, Fei Li, Fancong Kong, Ying Lu, Guowei Li, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2024-203359

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

Screening and Validation of Natural Product with Anti ETP-ALL Activity Using a Novel ETP-ALL Cell Line

Fenglin Li, Haihui Zhuang, Renzhi Pei, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5847.

https://doi.org/10.1182/blood-2024-204632

Published: 2024

Journal Articles

A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Hengwei Wu, Jimin Shi, Yi Luo, Jian Yu, Huarui Fu, Lizhen Liu, Xiaoyu Lai, Luxin Yang, Yishan Ye, Congxiao Zhang, Weijie Cao, Junjie Cao, Xiaojun Xu, Xiaoxia Hu, Ying Lu, He Huang, Yanmin Zhao

Blood (2024) 144 (Supplement 1): 1044.

https://doi.org/10.1182/blood-2024-206823

Published: 2024

Journal Articles

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2024-200064

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory chronic graft-versus-host disease

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

AP-3 targets the mrgbp/Tip60/MYC axis to exert potent anti T-ALL effects in a Notch1 independent manner

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: A multi-center study in China

Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent control

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia

Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial

A prospective, multicenter study on stem cell mobilization using EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Screening and Validation of Natural Product with Anti ETP-ALL Activity Using a Novel ETP-ALL Cell Line

A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only